Zachary E Stiles1, Sheema Khan2, Kurt T Patton3, Meena Jaggi2, Stephen W Behrman1, Subhash C Chauhan4. 1. Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, 38163, USA. 2. Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, 38163, USA. 3. Pathology Group of the Midsouth, Germantown, TN, 38138, USA. 4. Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, 38163, USA. Electronic address: schauha1@uthsc.edu.
Abstract
BACKGROUND: Intraductal papillary mucinous neoplasms (IPMN) are currently managed based on imaging characteristics and cyst fluid sampling. This study was designed to determine if MUC13, a glycoprotein aberrantly overexpressed in pancreatic adenocarcinoma, might aid in distinguishing high-risk lesions (high grade dysplasia/invasive disease) from low-grade lesions. METHODS: MUC13 immunohistochemical staining was performed on surgically resected formalin-fixed tissue specimens from 49 IPMNs and 23 non-mucinous cysts. Membranous MUC13 expression was measured by H-score, which quantifies staining intensity and the percentage of cells involved (range 0-300). RESULTS: MUC13 expression was detected in all IPMNs and was significantly greater than in non-mucinous cysts (median 210 vs 40, p < 0.001). MUC13 expression was similar among main (n = 26), branch (n = 15), and mixed (n = 8) duct lesions (median 210, 200, 225, respectively). The highest expression was observed in tumors with intestinal and pancreatobiliary histologic features (both median 225) and the lowest in gastric type lesions (median 200). MUC13 expression was significantly greater in high-risk lesions (n = 21) compared to those with low-grade dysplasia (n = 28) (median 250 vs 195, p < 0.001). CONCLUSION: MUC13 expression was significantly greater in high-risk IPMNs in this analysis. The preoperative assessment of MUC13 in cyst fluid samples warrants further investigation.
BACKGROUND:Intraductal papillary mucinous neoplasms (IPMN) are currently managed based on imaging characteristics and cyst fluid sampling. This study was designed to determine if MUC13, a glycoprotein aberrantly overexpressed in pancreatic adenocarcinoma, might aid in distinguishing high-risk lesions (high grade dysplasia/invasive disease) from low-grade lesions. METHODS:MUC13 immunohistochemical staining was performed on surgically resected formalin-fixed tissue specimens from 49 IPMNs and 23 non-mucinous cysts. Membranous MUC13 expression was measured by H-score, which quantifies staining intensity and the percentage of cells involved (range 0-300). RESULTS:MUC13 expression was detected in all IPMNs and was significantly greater than in non-mucinous cysts (median 210 vs 40, p < 0.001). MUC13 expression was similar among main (n = 26), branch (n = 15), and mixed (n = 8) duct lesions (median 210, 200, 225, respectively). The highest expression was observed in tumors with intestinal and pancreatobiliary histologic features (both median 225) and the lowest in gastric type lesions (median 200). MUC13 expression was significantly greater in high-risk lesions (n = 21) compared to those with low-grade dysplasia (n = 28) (median 250 vs 195, p < 0.001). CONCLUSION:MUC13 expression was significantly greater in high-risk IPMNs in this analysis. The preoperative assessment of MUC13 in cyst fluid samples warrants further investigation.
Authors: Brian B Haab; Andrew Porter; Tingting Yue; Lin Li; James Scheiman; Michelle A Anderson; Dawn Barnes; C Max Schmidt; Ziding Feng; Diane M Simeone Journal: Ann Surg Date: 2010-05 Impact factor: 12.969
Authors: Rosalie A Carr; Michele T Yip-Schneider; Scott Dolejs; Bradley A Hancock; Huangbing Wu; Milan Radovich; C Max Schmidt Journal: J Am Coll Surg Date: 2017-05-18 Impact factor: 6.113
Authors: Ajay V Maker; Nora Katabi; Li-Xuan Qin; David S Klimstra; Mark Schattner; Murray F Brennan; William R Jarnagin; Peter J Allen Journal: Clin Cancer Res Date: 2011-01-25 Impact factor: 12.531
Authors: Subhash C Chauhan; Mara C Ebeling; Diane M Maher; Michael D Koch; Akira Watanabe; Hiroyuki Aburatani; Yuhlong Lio; Meena Jaggi Journal: Mol Cancer Ther Date: 2011-10-25 Impact factor: 6.261
Authors: Thomas Zikos; Kimberly Pham; Raffick Bowen; Ann M Chen; Subhas Banerjee; Shai Friedland; Monica M Dua; Jeffrey A Norton; George A Poultsides; Brendan C Visser; Walter G Park Journal: Am J Gastroenterol Date: 2015-05-19 Impact factor: 10.864
Authors: Ajay V Maker; Linda S Lee; Chandrajit P Raut; Thomas E Clancy; Richard S Swanson Journal: Ann Surg Oncol Date: 2008-09-03 Impact factor: 5.344
Authors: Sheema Khan; Mara C Ebeling; Mohd S Zaman; Mohammed Sikander; Murali M Yallapu; Neeraj Chauhan; Ashley M Yacoubian; Stephen W Behrman; Nadeem Zafar; Deepak Kumar; Paul A Thompson; Meena Jaggi; Subhash C Chauhan Journal: Oncotarget Date: 2014-09-15
Authors: Katherine S Yang; Debora Ciprani; Aileen O'Shea; Andrew S Liss; Robert Yang; Sarah Fletcher-Mercaldo; Mari Mino-Kenudson; Carlos Fernández-Del Castillo; Ralph Weissleder Journal: Gastroenterology Date: 2020-12-07 Impact factor: 22.682